There’s an increasing amount value being created in Neuren, which, in my opinion, is not being translated to the share price.
I agree that $25 is a reasonable number if the next trial shows good safety and efficacy profile, but the sky is the limit if the following trial also has a similar result.
Share Price, page-10120
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.81 |
Change
0.460(3.21%) |
Mkt cap ! $1.834B | |||
| Open | High | Low | Value | Volume |
| $14.35 | $14.93 | $14.35 | $1.200M | 81.85K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 379 | $14.79 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.81 | 12 | 1 |
View Market Depth
| Last trade - 10.30am 27/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |